Clinical trials: Deep Venous Thrombosis
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Pulmonary Embolism, Medical Device Complication
Angel® Catheter Post Market Registry
This is a post-market, observational, retrospective multi-center Registry designed to gather information on the performance of the Angel® Catheter in general clinical practice.
- Conditions
- Pulmonary Embolism, Medical Device Complication, Deep Vein Thrombosis, Catheter Thrombosis
- Trial name
- NCT02917135
- Testing
- Angel® Catheter
- Where
- 5 sites in Germany, Italy and 1 more
- Volunteers
- 2,000 people
- Sponsor
- BiO2 Medical
Venous Thromboembolism, Deep Venous Thrombosis
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal…
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MAGNOLIA (NCT05171075)
- Testing
- Abelacimab, Dalteparin
- Where
- 117 sites in United States, Australia and 18 more
- Volunteers
- 417 people
- Sponsor
- Anthos Therapeutics, Inc.
Thrombolysis, Symptomatic Proximal Deep Vein Thrombosis
A Study to Learn More About How Well BAY3018250 Works and How Safe it is for People With Proximal Deep Vein Thrombosis
Researchers are looking for a better way to treat people who have deep vein thrombosis (DVT). DVT is a condition that occurs when a blood clot forms in a deep vein in the leg.
- Trial name
- SIRIUS (NCT06149520)
- Testing
- BAY3018250
- Where
- 68 sites in Belgium, Bulgaria and 11 more
- Volunteers
- 283 people
- Sponsor
- Bayer
Venous Thromboses, Venous Disease
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for…
- Conditions
- Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
- Trial name
- NCT05409976
- Testing
- GORE® VIAFORT Vascular Stent
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 136 people
- Sponsor
- W.L.Gore & Associates
Venous Thromboembolism
Safety and Efficacy Study of Fitaya Vena Cava Filter
A Multi-center, Randomized Controlled Trial to evaluate the safety and efficacy of Fitaya Vena Cava Filter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for deep vein thrombosis.
- Trial name
- NCT03691753
- Testing
- Fitaya Vena Cava Filter System, Aegisy Vena Cava Filter
- Where
- 13 sites in China
- Volunteers
- 186 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Anemia, Venous Thrombosis
A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)
This study is designed to investigate the incidence of deep vein thrombosis in patients receiving a perisurgical regimen of epoetin alfa (PROCRIT®) as compared to patients receiving standard of care blood conservation management.
- Trial name
- NCT00211146
- Testing
- epoetin alfa
- Volunteers
- 680 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Thrombosis, Deep Vein, Iliofemoral; Thrombosis
Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Acute Femoropopliteal DVT
This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate…
- Trial name
- DEXTERITY-AFP (NCT04862468)
- Testing
- Perivascular dexamethasone
- Where
- 22 sites in United States, Ireland and 1 more
- Volunteers
- 80 people
- Sponsor
- Mercator MedSystems, Inc.
Deep Vein Thrombosis, DVT
BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are…
- Trial name
- NCT05003843
- Testing
- Indigo Aspiration System
- Where
- 42 sites in United States
- Volunteers
- 229 people
- Sponsor
- Penumbra Inc.
Venous Thromboembolism
A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty
The objective of this study is to assess the efficacy and safety of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total knee arthroplasty.
- Trial name
- NCT01181102
- Testing
- edoxaban, enoxaparin sodium
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 716 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Thrombosis, Venous
Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)
To evaluate fondaparinux 2.5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.
- Trial name
- NCT00443053
- Where
- 227 sites in Bulgaria, Czechia and 15 more
- Volunteers
- 3,002 people
- Sponsor
- GlaxoSmithKline
Venous Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and…
- Trial name
- ADOPT (NCT00457002)
- Testing
- Apixaban, Enoxaparin
- Where
- 296 sites in United States, Argentina and 33 more
- Volunteers
- 6,758 people
- Sponsor
- Bristol-Myers Squibb
Deep Venous Thrombosis, Pulmonary Embolism
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
The purpose of this study is to demonstrate the ability of STA® Liatest® D-Di combined with a clinical pretest probability (PTP) to safely exclude pulmonary embolism (PE) or Deep Venous Thrombosis (DVT) in a 3 month follow-up.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, D-dimer
- Trial name
- DiET (NCT01221805)
- Where
- 18 sites in United States, Canada and 3 more
- Volunteers
- 2,040 people
- Sponsor
- Diagnostica Stago
Venous Thromboembolism, Deep Venous Thrombosis
The Protrieve PROTECTOR Study
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
- Trial name
- PROTECTOR (NCT06495996)
- Testing
- Percutaneous mechanical thrombectomy (PMT)
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Inari Medical
Deep Vein Thrombosis
Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT
Deep-vein thrombosis (DVT) is a common but under-diagnosed medical condition that occurs when a thrombus forms in one of the large veins, usually in the lower limbs, leading to either partial or complete blocked circulation.
- Trial name
- NCT01880216
- Testing
- Bemiparin sodium, Enoxaparin sodium
- Where
- 25 sites in Georgia, Russia
- Volunteers
- 312 people
- Sponsor
- Berlin-Chemie AG Menarini Group
Deep Vein Thrombosis
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the…
- Trial name
- NCT01516840
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 29 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Bayer
Venous Thrombosis Deep (Limbs), Venous Thrombosis
A Registry of the FLOWRUNNER Aspiration System for Patients With Symptomatic Venous Thrombosis
The objective of this study is to evaluate how well and how safe the FLOWRUNNER Aspiration System works for treating blood clots in the arms or legs in real-life medical settings.
- Trial name
- FAST (NCT07708376)
- Testing
- Mechanical Thrombectomy - Standard of Care procedure for venous thrombosis
- Volunteers
- 218 people
- Sponsor
- FlowPhysix, Inc.
Blood Circulation Disorder, Deep Vein Thrombosis
CEFID-I (CEra Flow Improves DVT-1)
The study is a single center clinical trial to evaluate the efficacy and safety of blood circulation improvement using an investigational medical device, which is a product on the market and it's name is Ceragem Master V6, for…
- Trial name
- NCT05469282
- Testing
- Blood circulation device
- Where
- South Korea
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Ceragem Clinical Inc.
Venous Thromboembolism, Atopic Dermatitis
The Incidence of Venous Thromboembolism in Atopic Dermatitis
This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.
- Conditions
- Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis
- Trial name
- NCT04969653
- Testing
- Exposure of venous thromboembolism
- Where
- United Kingdom
- Volunteers
- 754,745 people
- Sponsor
- Momentum Data
Deep Vein Thrombosis, Pulmonary Embolism
AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients
The purpose of this study is to investigate safety of apixaban in Japanese acute DVT/PE subjects when symptomatic DVT/PE subjects are treated with 10 mg BID apixaban for 7 days as initial therapy followed by 5 mg BID apixaban for…
- Trial name
- NCT01780987
- Testing
- Apixaban, Unfractionated Heparin (UFH), Warfarin
- Where
- 20 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Pfizer